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Table 1
Characteristics N¼20
Median age; years (range) 59 (26-72)
Male (%) 13 (65%)
Diagnosis, no. (%)
Acute Myeloid Leukemia 4 (20%)
Non-Hodgkin Lymphoma 11 (55%)
Chronic Leukemia (CLL or CML) 4 (20%)
Hemophagocytic syndrome 1 (5%)
Disease risk, no. (%)
High risk 5
Intermediate risk 10
Low risk 4
Prior autografting, no. (%)
Yes 1 (5%)
No 19 (95%)
Donors, no. (%)
Related 5 (25%)
Unrelated 15 (75%)
Sex mismatch, no (%)
M to M 9 (45%)
M to F 3 (15%)
F to M 4 (20%)
F to F 4 (20%)
Degree of HLA match, no. (%)
10/10 19 (95%)
9/10 1 (5%)
Median KPS; (range) 80 (70-100)
Median HCT-CI; (range) 1 (0-5)
Median CD34 cell dosey (106 cells/kg recipient body weight),
(range)
5.7 (1.5-11.3)
Abstracts / Biol Blood Marrow Transplant 19 (2013) S313eS341 S339summarizes cohort data. Elevated Kyn/Trp ratio correlated
with GVHD compared to non-GVHD cohort (p ¼ 0.027).
LikewiseAUCKyn/Trp ratio correlatedwithGVHD (p¼0.007).
Mortality rate was 50% at a median of 98 days post-HSCT.
Conclusions: IDO activity is associated with acute GVHD and
may be a useful biomarker to assist with GVHD diagnosis.
Future validation studies are needed to conﬁrm these ﬁnd-
ings, which should be considered in clinical trials that target
IDO induction for prevention or treatment of GVHD
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We have used home care as an option to hospital-care during
the pancytopenic phase after hematopoietic allogeneic stem
cell transplantation (HSCT) for 15 years at Karolinska
University Hospital . This is now an opportunity for children
as well as for adults. A nurse from the unit visited and
checked the patient regularly.
After treating 146 patients at home we compared them to
hospital controls matched for sex, age, diagnosis, stage of
disease, type of donor, source of stem cells and conditioning.
Oral intake was intensiﬁed from September 2006 and
improved (P ¼ .002). More calories per day was associated
with less GVHD in an univariate analysis (P ¼ .02). In multi-
variate analysis grades 0eI GVHD was associated with home
care (HR¼2.46, P ¼ .02) and with days spent at home
(HR¼0.92, P¼ .005), but notwith oral nutrition (HR¼0.98, P¼
.13). Transplant-related mortality, chronic GVHD and relapse
were similar in the groups. Five-year survival was 61% in the
home care group as compared to 49% in the controls (P¼ .07).
When we analyzed outcome of HSCT for the past two
decades, we found that low transplant-related mortality
(TRM) was associated with age (P < .001), acute leukemia (P
¼ .002), HLA-identical related donor (P < .001), reduced
intensity conditioning (P ¼ .007) and home care (P ¼ .02).
Wecollectedall in-andoutpatient costsduring twoyearsatour
unit. Costsduring the initial transplantperioduntil day76were
signiﬁcantly lowerwith home care inmultivariate analysis (RH
0.8,P ¼ .035). Increased costs were associated with a second
transplant, T-cell depletion, adults, G-CSF and complications.
To show Quality of life we used The Sympathy- Acceptance-
Understanding-Competence-questionnaire (SAUC) instrument
developed from the SAUC-model. This study aim to describe
patients’ experiences of care and support from healthcare staff
while treated in hospital or at home during the early post
transplantationphase afterHSCT. The studyshowedhomecare
to beas satisfactoryashospital-care. Also24 relatives staying at
home together with the patients gave their opinion regarding
quality of life. Eleven questions were asked in a survey with
a scale from 1-5 where 1 was very satisfactory and 5 was the
opposite. 21 rated 1-2 very satisfactory and three rated 2-3.
Conclusion: Home care is safe and cheaper than hospital
care. Home care and many days spent at home were corre-
lated with a low risk of acute GVHD. Home care was also
associated with a lower TRM and a trend for better survival.461
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Non-myeloablative (NMA) conditioning with total lymphoid
irradiation and antithymocyte globulin (TLI/ATG) has been
shown to protect against acute graft-versus-host disease
(GVHD), while preserving graft-versus-malignancy effects.
Reported here is our institutional experience with allogeneic
hematopoietic cell transplantation (allo-HCT) following TLI/
ATG conditioning. Criteria used to select TLI/ATG condi-
tioning included; age 65 and/or HCT-CI of >3. Patients
received ATG (1.5 mg/kg/day) from day -11 through -7 and
a total dose of 8Gy of TLI administered from day -11 through
-1 followed by cell infusion of day 0. GVHD prophylaxis
consisted of combination of either cyclosporine/mycophe-
nolate mofetil (MMF) or tacrolimus/MMF in those under-
going a matched sibling or unrelated donor allo-HCT,
respectively. Table 1 summarizes the baseline patient char-
acteristics (n¼20). The median follow up for surviving
patients is 723 days (range 180-1364 days). All patients
engrafted, except onewho experienced primary engraftment
failure. The median time to neutrophil engraftment was 16
days (range 9-23 days) and platelet engraftment was 10 days
(range 6-24 days). Median donor chimerism on days +30,
+100 and +365 was 93% (range 60-100%), 95% (range 54-
Abstracts / Biol Blood Marrow Transplant 19 (2013) S313eS341S340100%), and 100% (range 56-100%) respectively. Cumulative
incidence (CI) of grade II-IV acute GVDHwhile accounting for
competing events, at day +100 was 34.2% (n¼6) and 46.2%
(n¼8) at day +180. The CI for grade III-IV acute GVHD was
22% (n¼4) at day +100, and 29.4% (n¼5) at day +180. CI of
chronic GVHD (cGVHD) was 50.5% at one year. CI of limited
and extensive chronic GVHD was 22.1% (n¼3) and 29.2%
(n¼4), respectively at one year. The CI of relapse was 11.7%
(n¼2) at one year. The non-relapse mortality (NRM) was 0%
at day +100 and 14.7% (n¼2) at one year. Causes of death
include disease relapse (n¼2), GVHD (n¼2), and accident
(n¼1). The overall and progression free survival at one year is
73.5%. Our limited, retrospective data show encouraging
relapse and NRM rates with TLI/ATG-based NMA condi-
tioning, but with higher than previously reported rates of
acute and chronic GVHD, underscoring the need for novel
strategies designed to effectively prevent GVHD.
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Background: Donor T cell activation in response to alloanti-
gens presented by host antigen presenting cells (APC) is
a critical step in the pathophysiology of Graft Versus Host
Disease. The macrolide Azithromycin (Azi) is studied in lung
transplant and allogeneic hematopoietic cell transplant (HCT)
recipients to decrease graft rejection and progression of lung
injury, respectively.WenowtestedwhetherAzi plays a role in
the modulation of adaptive immune responses by deter-
mining its effects on alloantigen-dependent T cell activation.
Methods: In vitro: Mixed lymphocyte reactions (MLR) using
C57BL/6 (H2b) T cells as responders and B6D2F1 (H2bd) or
BALB/c (H2d) splenocytes as stimulators, as well as TCR
dependent, alloantigen-independent CD3/CD28 or lectin-
type stimulation (Concavalin) assays of C57BL/6 Tcells were
performed in the absence or presence of Azi at varying
concentrations 5mg/ml, 10mg/ml, 20mg/ml, 50mg/ml. T cell
proliferation was assessed by 3HT-uptake. T cells were phe-
notyped and supernatant was tested for cytokine expression.
In vivo: B6D2F1 were pretreated for 2 weeks with Azi at
a dose of 3mg/ml drinking water or received untreated water
as control. Then, animals were conditioned with 12Gy TBI
and transplanted with 4X10E6 bone marrow cells and
6X10E6 splenocytes from allogeneic C57BL/6 donors.Azithromycin (mg/ml)
0 5
MLR cpm 20053  1041 17497  12
IFNg (pg/ml) 590.5  59.9 476.0  42
TNF (pg/ml) 139.1  8.0 114.2  5.
IL-2 (pg/ml) 27.0  0.6 23.4  1.
IL-10 (pg/ml) 115.5  8.8 99.1  14
IL-17 (pg/ml) 24.7  0.9 19.3  3.
IL-4 (pg/ml) d d
IL-6 (pg/ml) 169.3  8.3 139.6  16
%CD4+FOXP3+ 2.5  0.1 2.9  0.
Con A cpm 61791  4529 64350  36
CD3/CD28 cpm 54868  1873 51182  20
cpm ¼ counts per minute
d ¼ below assay sensitivity
* p < 0.05
** P < .01Recipients continued to receive Azi-supplemented or
untreated water, and on day+7, splenic T cell expansion and T
cell phenotyping were done.
Results: AlloreactiveTcell proliferation invitro showedanAzi
dose-dependent decline at 96 hours along with reductions in
TNF, IFNg, IL-2, IL-6, L-10, IL-17. Interestingly, a signiﬁcant
relative expansion of CD4+FOXP3+ T cells (Tregs) within the
CD4+ T cell fraction was observed with increasing Azi-levels
from2.50.1% (0mg/ml) to 5.00.2% (50mg/ml).Nodifferences
in T cell proliferation were seen when T cell stimulation
occurredAPC-independenteither via ConcavalinAor via CD3/
CD28 except for slight suppression at Azi 50 mg/ml. In vivo,
whencompared to controls, pretreatmentwithAzi resulted in
decreased splenic expansion of both CD4+ T cells
(2.1X10E60.2 vs. 4.3X10E60.6, P < .01) and CD8+ T cells
(4.9X10E60.5 vs. 6.4X10E60.4, P < .05) along with a slight
and non-signiﬁcant increase of Tregs (1.5 0.3% vs 1.10.1%).
Conclusion: Azithromycin suppresses alloreactive T cell re-
sponse in vitro and in vivo, paralleled by the induction of Tregs,
supporting its use in lung transplantation and allogeneic HCT.463
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